Skip to main content
Premium Trial:

Request an Annual Quote

Illumina Licenses Orchid Cellmark's Nucleotide Extension IP

NEW YORK (GenomeWeb News) – Orchid Cellmark has licensed part of its diagnostic and forensics intellectual property portfolio to Illumina in exchange in for an upfront fee, potential milestone payments, and royalties.

The license for Orchid's single base nucleotide extension technology includes an $850,000 license fee, a potential $150,000 in milestone payments, and royalties from Illumina through any subcontracting agreements. Orchid also will be able to buy certain Illumina products utilizing the patents as a preferred customer.

Orchid retains the rights to use the licensed patents in all fields of use.

"This transaction allows Orchid to work with Illumina to further strengthen our long term competitive position in providing DNA forensic testing services," Thomas Bologna, Orchid Cellmark's president and CEO, said in a statement.

The Scan

And a Fourth?

A fourth dose of the Pfizer-BioNTech SARS-CoV-2 vaccine in an Israeli study increased antibody levels but did not prevent Omicron variant infections, according to the Financial Times.

For Better Science Software

A virtual institute funded by former Google CEO Eric Schmidt's philanthropy aims to lure software engineers to academia, Science reports.

Recommendation Explanations

The New York Times writes that the US Centers for Disease Control and Prevention is straining to both make and explain decisions based on limited information.

Genome Research Papers on De Novo Mutation Rates, Polyploid Genotyping, Oncogene Epigenomic Translocation

In Genome Research this week: de novo mutations rates in hemoglobin subunits, analysis of variant calling methods for polyploid plants, and more.